Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor
about
LRP-1: a checkpoint for the extracellular matrix proteolysisCloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysisDirect binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activityThe receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexesVEGF-initiated angiogenesis and the uPA/uPAR systemProcessing of complex between urokinase and its type-2 inhibitor on the cell surfacePlasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth.Clathrin and LRP-1-independent constitutive endocytosis and recycling of uPAR.The plasmin cascade and matrix metalloproteinases in non-small cell lung cancerCytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors.Anthrax toxin: structures, functions and tumour targeting.Plasminogen activator inhibitor-1 in the pathogenesis of asthma.Regulatory elements involved in constitutive and phorbol ester-inducible expression of the plasminogen activator inhibitor type 2 gene promoteralpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)-dependent internalization of the urokinase receptorIs plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?Impact of the Pla protease substrate α2-antiplasmin on the progression of primary pneumonic plague.Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells.Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.Plasminogen activation by human keratinocytes: molecular pathways and cell-biological consequences.An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines.The expression and localization of urokinase-type plasminogen activator and its type 1 inhibitor are regulated by retinoic acid and fibroblast growth factor in human teratocarcinoma cells.Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.Structure-function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins.E2F1-mediated transcriptional inhibition of the plasminogen activator inhibitor type 1 gene.Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes.Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effectUrokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells.Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.PMA-induced down-regulation of the receptor for alpha 2-macroglobulin in human U937 cells.Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradationPhosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility.Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia.Type 1 plasminogen activator inhibitor gene expression following partial hepatectomy.Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity.Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin.Fibroblast growth factor-2 did not restore plasminogen system activity in endothelial cells on glycated collagen.urokinase plasminogen activator (two-chain):uPAR + plasminogen activator inhibitor 1 (PAI-1) -> PAI-1:urokinase plasminogen activator (two-chain):uPAR
P2860
Q21285122-21602179-F3D7-4DD4-9A76-422F7B27E812Q24299135-D0D7D18D-04C5-4458-A171-8CCBF285801DQ24633333-C08D40D7-312C-442F-A6BE-5AB74985CCC8Q24678932-9BCDABF6-BD60-49C1-8C45-C27BC2DCDD8FQ27025897-B82D3C5D-98C1-471E-9B00-F053991557AAQ29306421-AB265B1E-EBE1-41AF-B23D-35A2BA8BB976Q30307084-E1617B12-A415-437C-9BA9-891E090A4151Q33384446-1FED9A46-C258-4B77-BBB4-9515C892A1B7Q33634208-226BA1C6-406B-4104-A94B-3695C7393E4FQ33895912-40B4CF5C-153F-49C7-9C91-165625A1E3CEQ35184740-22D0D908-13AE-40F8-A156-FA7B4E67FB26Q35634264-57460AF2-1205-4E19-9066-E7CF1854ADD9Q35772792-2C2C206F-A4FA-495C-A27F-39E553561A79Q36236343-B393F140-C674-4A23-B62E-6F3CA54C4D10Q36237406-3ED36391-EA7A-4AE0-A821-DF89BBDFA54AQ36281274-BB7F6392-C966-4094-89FD-5ED8BE4A29F9Q36324236-8AE4E469-2B83-4E96-A9AC-DDE188F5EA79Q36741529-2DE8E0C4-3AA6-4677-BE3F-600093FF7488Q37720834-5D059EA1-FA95-47DD-8FE0-48D2706D9FE5Q39846676-AECB1A54-25F2-4664-944D-198EDBD5A042Q40444813-725EF8CC-5027-4A53-B2C2-117911DCA8BBQ40512241-0935F21D-BE73-45D4-B930-4564A83AB918Q40642393-701B2B32-983E-4EB9-B0E9-43525870C887Q40642976-E07763D6-84B8-4ABB-8ADC-499BDED6DA52Q40683497-DBFFA94B-8A7A-4F25-946C-8F692D0AADA1Q40780336-9178080C-4770-4323-9F14-B92267FAD59DQ40814192-FC87D1D5-EA6F-45C7-B766-FE0FA3D84467Q41064411-2473CA3C-D78F-4164-B450-617BD13710C4Q41083036-452E18A1-92E3-477D-A59D-6C4FAC0C7210Q41206436-F0C25572-FA52-4B85-B2E8-19CAE6DDD23BQ41380094-52EA25B2-66FA-449F-8D5E-406B0DD862B0Q41832676-D6B2360F-617D-4CEA-8B19-E360B0C18589Q42209596-0E6C3C5E-4BFF-47E1-8EE1-35E966712463Q42453965-D0D2DDEC-5C7E-4DB6-906B-6CDDC75FC89EQ42754410-D89C2A2C-87A3-4973-A4B7-91128C29AE59Q44111674-FBDDE412-F375-4DCE-946D-1E0F43427CC1Q44779601-FD379604-7B84-4057-A2DC-6429383EA49DQ46412954-31B159CD-6F7D-425C-946F-B373AEC331C8Q47137588-4EBAD89C-1A52-4E51-8D76-F2D9F4027CDFQ50291258-11BEF418-7825-4979-83FB-66D0C2394E8F
P2860
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor
description
1989 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
article publié dans les Procee ...... f the United States of America
@fr
artículu científicu espublizáu en 1989
@ast
im Juli 1989 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1989/07/01)
@sk
vědecký článek publikovaný v roce 1989
@cs
wetenschappelijk artikel (gepubliceerd op 1989/07/01)
@nl
наукова стаття, опублікована в липні 1989
@uk
name
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor
@ast
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor
@en
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor
@nl
type
label
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor
@ast
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor
@en
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor
@nl
prefLabel
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor
@ast
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor
@en
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor
@nl
P2093
P2860
P356
P1476
Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor
@en
P2093
P2860
P304
P356
10.1073/PNAS.86.13.4828
P407
P577
1989-07-01T00:00:00Z